Appeals court says Hanmi product does not infringe Nexium patent

|By:, SA News Editor

A U.S. court of appeals has affirmed a district court's ruling that Hanmi has not infringed AstraZeneca's (AZN) '504 patent.

The court determined that "the written description limits 'alkaline salt' in the '504 patent to certain specifically named salts."

Ultimately, this means the district court's ruling of noninfringement is upheld.

AZN "respectfully disagrees" and will consider a "further appeal," Reuters notes.

Full decision